glp-1 and neuroinflammation drugs calm inflammation beyond diabetes weight loss Glucagon-like peptide-1 medicines in neurological

Key considerations from available evidence: No direct hormonal mechanism linking tirzepatide to menstrual disruption has been identified Metabolic improvements (reduced insulin resistance, decreased androgens) may benefit women with PCOS The magnitude and rapidity of weight loss correlate with likelihood of temporary menstrual changes Long-term data on reproductive outcomes remain limited Healthcare providers should counsel women of reproductive age about potential menstrual changes when initiating tirzepatide

[1] As documented in the SmPC and European Public Assessment Report (EPAR), a common cardiovascular effect observed with Wegovy is a modest increase in resting heart rate, typically by 1-4 beats per minute on average

Keywords: GLP-1, GIP, pharmacokinetics, drugdrug interactions, physiologically based pharmacokinetic model Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are peptide hormone-derived analogs classified as incretin mimetic drugs (Figure 1)

Stop chasing shadows in the market

G.ChoppM

We described the cumulative incidence of treatment discontinuation in all patients and treatment reinitiation among those who discontinued treatment using the AalenJohansen estimator